Vanguard Personalized Indexing Management LLC Raises Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Vanguard Personalized Indexing Management LLC boosted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.1% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 10,201 shares of the company’s stock after acquiring an additional 497 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in IDEXX Laboratories were worth $4,970,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the business. Riverview Trust Co purchased a new stake in shares of IDEXX Laboratories during the first quarter valued at $26,000. Crewe Advisors LLC bought a new stake in IDEXX Laboratories during the 1st quarter valued at about $26,000. Ridgewood Investments LLC purchased a new stake in IDEXX Laboratories in the 2nd quarter valued at about $27,000. Institutional & Family Asset Management LLC purchased a new stake in IDEXX Laboratories in the 2nd quarter valued at about $28,000. Finally, DSM Capital Partners LLC bought a new position in IDEXX Laboratories in the 4th quarter worth about $33,000. Institutional investors own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on IDXX. Stifel Nicolaus decreased their price target on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a research note on Monday, June 24th. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, July 10th. Piper Sandler dropped their price target on IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 14th. Finally, BTIG Research started coverage on IDEXX Laboratories in a report on Thursday, July 25th. They issued a “buy” rating and a $580.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $582.25.

IDEXX Laboratories Trading Down 0.2 %

IDXX opened at $511.30 on Thursday. IDEXX Laboratories, Inc. has a 12 month low of $372.50 and a 12 month high of $583.39. The stock has a fifty day moving average price of $482.98 and a 200-day moving average price of $499.90. The firm has a market cap of $42.23 billion, a price-to-earnings ratio of 49.50, a PEG ratio of 4.17 and a beta of 1.33. The company has a current ratio of 1.37, a quick ratio of 1.03 and a debt-to-equity ratio of 0.33.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Tuesday, August 6th. The company reported $2.44 EPS for the quarter, missing the consensus estimate of $2.88 by ($0.44). IDEXX Laboratories had a net margin of 22.34% and a return on equity of 57.03%. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $1.01 billion. During the same period in the previous year, the company posted $2.67 earnings per share. The business’s quarterly revenue was up 6.4% compared to the same quarter last year. As a group, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 10.45 earnings per share for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.